AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01290874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: Tiotropium bromide 18 mcg once daily for one year of treatment.
Study NCT01290874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol
Description: Salmeterol 50 mcg twice daily for one year of treatment.
Study NCT01290874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol
Description: Formoterol 12 mcg twice daily for one year
Study NCT02532894 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic cigarette
Description: Inhaling e-cigarette vapor
Study NCT03754075 — intervention group
Intervention type: PROCEDURE
Intervention: Complete mesocolic excision
Description: The resection was based on the principles of CME. The superior mesenteric vein was exposed to perform central vessel ligation and lymph nodes dissection. Extended right hemicolectomies for tumors located from the ascending colon close to the hepatic flexure and distally were performed openly as standard during the study period. These resections included the prepyloric and gastroepiploic lymph nodes dissection.
Study NCT03754075 — intervention group
Intervention type: PROCEDURE
Intervention: Conventional colon resections
Description: The patients underwent what was considered standard colon cancer resections in Denmark during the study period.
Study NCT02304107 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FSH
Description: 75IU daily for 7 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding. If the follicle does not exceed 9mm the dose will be increased by 37.5IU every 7 days
Study NCT02304107 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: 70 women will receive Letrozole (Femara®, Novartis, Switzerland) 2.5mg twice daily for 5 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding.
Study NCT03080844 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delay time to first cigarette
Description: Participants asked to delay time until they smoke first cigarette of the day.
Study NCT03080844 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapy
Description: Participants receive tips on how to resist the urge to smoke and control cravings to smoke.
Study NCT03080844 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy
Description: Participants receive tips on how to resist the urge to smoke and control cravings to smoke.
Study NCT00616122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00616122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Study NCT00616122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Study NCT00616122 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT03283826 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATA188
Description: ATA188 is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ progressive multiple sclerosis.
Study NCT03283826 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to ATA188
Study NCT03921424 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114
Description: 15-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) present in Prevnar 13™ plus 2 additional serotypes (22F, 33F) in each 0.5 mL dose.
Study NCT03921424 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13™
Description: 13-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) in each 0.5 mL dose.
Study NCT03921424 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PNEUMOVAX™23
Description: 23-valent pneumococcal polysaccharide vaccine containing 23 serotypes (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F) in each 0.5 mL dose
Study NCT03921424 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PNEUMOVAX™23
Description: 23-valent pneumococcal polysaccharide vaccine containing 23 serotypes (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F) in each 0.5 mL dose
Study NCT02587650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capmatinib
Description: Given PO
Study NCT02587650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceritinib
Description: Given PO
Study NCT02587650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib
Description: Given PO
Study NCT02587650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02587650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Given PO
Study NCT02898532 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational programmes
Description: Children with ADHD or ADHD-like symptoms practicing target shooting sport in Danish Shooting Associations, during schooltime, for 6 months.
Study NCT01246583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550 Ointment 1
Description: 2% CP-690,550 Ointment 1 twice daily for 4 weeks
Study NCT01246583 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle 1
Description: Vehicle 1 twice daily for 4 weeks
Study NCT01246583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550 Ointment 2
Description: 2% CP-690,550 Ointment 2 twice daily for 4 weeks
Study NCT01246583 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle 2
Description: Vehicle 2 twice daily for 4 weeks
Study NCT02132481 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMA Only
Description: The EMA only condition consists of: a) RSAU, b) an Android phone, c) a 6-hour EMA training on how to use the phone, HIV and SUD prevention, self-monitoring, procedures for completing the EMAs (see Appendix), d) an EMA signaling schedule covering 6 EMA prompts over a 16-hour time period per day tailored to each participant's schedule, e) research office visits twice a week during 1st month for staff to check participant's proficiency using the phone and completing EMAs, and f) collecting urine screens.
Study NCT02132481 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMI Only
Description: The EMI only condition includes: a) RSAU, b) an Android phone, c) a 6-hour EMI training on how to use the phone, HIV and SUD prevention, how each EMI relates to relapse prevention or HIV risk reduction, and how to access each EMI, d) research office visits twice weekly in 1st month as described above except visits focus on EMIs, and e) collecting urine screens.
Study NCT02132481 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMA+EMI
Description: The combined condition includes: a) RSAU, b) an Android phone, c) the 6-hour EMA training, d) EMA signaling schedule, e) the 6-hour EMI training, f) research office visits 2 times a week during 1st month, and g) feedback following each EMA, which will include participants' current risk of use in the next 7 days .
Study NCT02132481 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neither - RSAU
Description: The neither smartphone condition will still have access to community recovery support as usual (RSAU). Standard discharge practice is to provide a recovery plan and relevant referrals. A recent RCT indicated that after leaving treatment, 37% of the clients attended self-help in the community, 41% participated in substance-free structured activities, and about 14% returned to treatment within 6 months. They will also participate in office visits twice a week during 1st month to complete non-phone related surveys and provide urine for screens.
Study NCT02132481 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neither - RSAU
Description: The neither smartphone condition will still have access to community recovery support as usual (RSAU). Standard discharge practice is to provide a recovery plan and relevant referrals. A recent RCT indicated that after leaving treatment, 37% of the clients attended self-help in the community, 41% participated in substance-free structured activities, and about 14% returned to treatment within 6 months. They will also participate in office visits twice a week during 1st month to complete non-phone related surveys and provide urine for screens.
Study NCT01471782 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Administered by continuous intravenous infusion
Study NCT01696526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vitamin D fortified fish
Description: fish containing vitamin D3
Study NCT01696526 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: conventional fish
Description: fish containing low concentrations of vitamin D3
Study NCT05054114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon gamma human recombinant (IFN-G)
Description: nasal form
Study NCT04203524 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Procalcitonin Levels
Description: Procalcitonin (PCT) will be measured within 48 hours of admission to the ICU or 48 hours of onset of sepsis (if developed during the ICU stay). In addition, the patients will have daily blood samples taken up to 5 days or until ICU transfer, whichever occurs first. A PCT-guided algorithm will be available to guide the management of patients in the PCT group.
Study NCT04203524 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Procalcitonin (PCT) will be measured within 48 hours of admission to the ICU or 48 hours of onset of sepsis (if developed during the ICU stay). In addition, the patients will have daily blood samples taken up to 5 days or until ICU transfer, whichever occurs first.The results of the PCT levels obtained will be blinded and all clinical team members will not be able to access the results.
Study NCT00584155 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline and 0.3% ofloxacin
Description: The patient will be instructed to place one dropper full of solution in the external auditory canal. The bottle will be marked right or left ear and are only to be used in the designated ear. The drops will be administered at the start time, 30 minutes after chemotherapy starts and hourly for 4 hours after infusion.
Study NCT00584155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactated Ringer's with 0.03% Ofloxacin
Description: The patient will be instructed to place one dropper full of solution in the external auditory canal. The bottle will be marked right or left ear. The drops will be administered at the start time, 30 minutes after chemotherapy starts and hourly for 4 hours after infusion.
Study NCT00349856 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biofinity
Description: Soft contact lens
Study NCT02544711 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient specific instrument
Description: The proposed innovation consists in using patient specific instrument (PSI) for tumor resection. It is compounded of a preoperative assistance to plan the surgery and an intraoperative assistance to reproduce the preoperative planning.
Study NCT02544711 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conventional surgical treatment
Description: The conventional treatment is planned on two-dimensional images (CT and MRI).
Study NCT03784079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254
Description: GSK3640254 will be available with dosing strengths of 5 mg, 20 mg, and 100 mg to be administered as an oral capsule along with 240 mL of water.
Study NCT03784079 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching GSK3640254 Mesylate salt
Description: Placebo to match GSK3640254 Mesylate salt will be given as an oral capsule along with 240 mL of water
Study NCT02231151 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The type of CPR error(s) shown to the individual
Description: Participants will be randomly assigned 12 videos to watch and rate the CPR quality of each. Investigators will be blind to the identity of the participants.
Study NCT03235648 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cardiophrenic lymph nodes resection
Description: surgical resection
Study NCT00128479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mifepristone
Description: mifepristone 300 mg daily for 7 dats
Study NCT00128479 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: mifepristone matched placebo
Description: daily for 7 days
Study NCT00128479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mifepristone 600 mg
Description: mifepristone 600 mg daily for 7 days
Study NCT00128479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mifepristone 1200 mg
Description: mifepristone 1200 mg daily for 7 days
Study NCT01443520 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subjects will be given orally placebo twice a day for 8 days prior to the study.
Study NCT01443520 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: The subjects will be given orally duloxetine 30mg twice a day for 8 days prior to the study.
Study NCT01443520 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine
Description: The subjects will be given orally venlafaxine 37,5mg twice a day for 8 days prior to the study.
Study NCT03870438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine Oral Solution
Description: In the intervention arm, HIV-1 negative children with HIV-1 positive mothers who have an HIV-1 viral load ≥ 1000 copies/ml will receive lamivudine syrup orally (7.5 mg twice daily if 2 to 4 kg; 25 mg twice a day if weight \<8 kg; and 50 mg twice a day if weight >8 kg). The intervention will last a maximum of 10 months (until the baby is 12 months old or until the confirmed end of breastfeeding). Breastfeeding will be considered to be ceased if the mother confirms she is no longer breastfeeding for 2 consecutive monthly visits
Study NCT03488173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole capsules
Description: Test 1: 30 healthy volunteers will be included and randomized into 3 groups (10 for each). During the study session, subjects will receive a single dose of Lansoprazole capsules 30 mg in sequence of T-R-R in group A; R-T-R in group B; and R-R-T in group C.~Test 2: 12 healthy volunteers will be recruited and randomized to 2 groups (6 for each). Subjects in group A will receive a single dose of experimental drug in sequence of fast-fed condition; while in group B, subjects will receive the same dose and drug but in fed-fast order.
Study NCT03488173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole capsules
Description: Test 1: 30 healthy volunteers will be included and randomized into 3 groups (10 for each). During the study session, subjects will receive a single dose of Lansoprazole capsules 30 mg in sequence of T-R-R in group A; R-T-R in group B; and R-R-T in group C.~Test 2: 12 healthy volunteers will be recruited and randomized to 2 groups (6 for each). Subjects in group A will receive a single dose of experimental drug in sequence of fast-fed condition; while in group B, subjects will receive the same dose and drug but in fed-fast order.
Study NCT01270308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Lansoprazole DR Capsules 30 mg
Study NCT01270308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: Lansoprazole DR Capsules 30 mg
Study NCT00960336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin hydrochloride
Study NCT03581786 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TORIPALIMAB INJECTION(JS001 ) combine with chemotherapy
Description: TORIPALIMAB INJECTION(JS001 ) combine with chemotherapy
Study NCT03581786 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: placebo combine with chemotherapy
Study NCT03151863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioids
Description: The usual opioid treatment used for nursing care
Study NCT03151863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine is provided intranasally
Study NCT03151863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Normal saline is either given subcutaneously or intranasally
Study NCT03151863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline is either given subcutaneously or intranasally
Study NCT02448602 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: acupuncture
Description: Patients will be treated with Shenmen(HT7), needle 1 times a day, 30 min/time, 5 days for a period of treatment, the treatment interval for two days, five intervention treatment, follow-up after 4 weeks.
Study NCT02448602 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: acupuncture
Description: Patients in Sancai coordinated points group, will be treated with Baihui(DU20), Shenmen(HT7), Sanyinjiao(SP6), needle 1 times a day, 30 min/time, 5 days for a period of treatment, the treatment interval for two days, five intervention treatment, follow-up after 4 weeks.
Study NCT02448602 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: acupuncture
Description: Patients in Control group, will be treated with at the junction of deltoid and biceps, needle 1 times a day, 30 min/time, 5 days for a period of treatment, the treatment interval for two days, five intervention treatment, follow-up after 4 weeks.
Study NCT01251653 — intervention group
Intervention type: DRUG
Intervention: Afatinib
Description: Maximum Tolerated Dose of Afatinib in combination with gemcitabine
Study NCT01251653 — intervention group
Intervention type: DRUG
Intervention: docetaxel
Description: Maximum Tolerated Dose of Afatinib in combination with docetaxel
Study NCT01251653 — intervention group
Intervention type: DRUG
Intervention: gemcitabine
Description: Maximum Tolerated Dose of Afatinib in combination with gemcitabine
Study NCT02268279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solithromycin
Study NCT02707120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRGF-Endoret
Description: Active treatment will be PRP eye drops obtained by the PRGF-Endoret system.
Study NCT02707120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artificial tears eye-drops
Description: Artificial tear moisturizing eyedrops (Hidrathea®, Nacl 0.9 % solution without preservatives).
Study NCT03333720 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phenylalanine-free protein substitute tablets
Description: Thirty eligible PKU patients (≥ 8 years), identified as current tablet users, will be recruited to this study. Patients will firstly observe a 7-day baseline period. During baseline, patients will continue with their existing diet and protein substitute prescription before receiving Phenylalanine-free protein subsitute tablets daily for 28 days in addition to appropriate nutritional management.
Study NCT01012791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zumba exercise
Description: Subjects with do Zumba exercise for approximately 60 minutes twice a week for 6 months.
Study NCT04284202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 plus Dasatinib
Description: Toripalimub 240mg injection day1; Dasatinib 100mg po qd day1-day21. 3weeks is 1 cycle.
Study NCT02137512 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-Loop Control System
Description: This investigational device system included the following components:~* DiAs - a smart-phone medical platform;~* Dexcom G4 Platinum CGM system connected to DiAs via CGM receiver and USB-Bluetooth relay hardware;~* Roche Accu-Chek insulin pump connected to DiAs via wireless Bluetooth;~* Remote Monitoring Server connected to DiAs via 3G or local Wi-Fi network~* Modular Closed-Loop Control Algorithm Running on DiAs, which is of Control-to-Range (CTR) class
Study NCT02137512 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sensor-Augmented Pump (SAP)
Description: This commercial device system included the following components:~* Dexcom G4 Platinum CGM system;~* Roche Accu-Chek insulin pump
Study NCT04012554 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: avoid chest drainage tube placement after video-assisted thoracoscopic wedge resection of lung
Description: Avoiding chest drainage tube placement after VATS of the lung in the experiment group.
Study NCT04012554 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Indewlling chest drainage tube after video-assisted thoracoscopic wedge resection of lung
Description: Indewlling chest drainage tube after VATS of lung in the control group.
Study NCT03906097 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Play and Competition-Based Cognitive Therapy
Description: The intervention group was received play and competition-based cognitive therapy for 10 weeks, 3 days a week, 1 hour per day; the control group was the group who continued the special education program
Study NCT03650842 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near infrared spectroscopy (NIRS)
Description: One monitor will be placed on the forehead to measure cerebral oxygenation and a second over the lower back to measure tissue (muscle or renal) oxygenation.